- €2.29bn
- €294.52m
- CH₣112.24m
- 69
- 42
- 79
- 73
Annual cashflow statement for BB Biotech AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | -46.7 | -59.5 | -44.3 | -35.3 | -31.1 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 262 | -94.8 | 231 | 218 | 305 |
| Financing Cash Flow Items | -0.883 | -0.986 | -1.73 | -5.8 | -4.98 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -284 | 91.8 | -233 | -220 | -305 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -23.9 | -3.98 | -0.887 | -1.45 | -0.043 |